• <track id="ituhu"></track><menuitem id="ituhu"><strong id="ituhu"></strong></menuitem>
    <track id="ituhu"><div id="ituhu"></div></track>
    <samp id="ituhu"><strong id="ituhu"></strong></samp>
    <track id="ituhu"><span id="ituhu"></span></track><bdo id="ituhu"></bdo>
  • <div id="ituhu"><em id="ituhu"></em></div>
  • <track id="ituhu"><span id="ituhu"></span></track>

    ×

    Do you want to link to this External Site and leave Amgen.com?

    YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

    ×

    Do you want to link to this External Site and leave Amgen.com?

    YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

    ×

    Do you want to link to this External Site and leave Amgen.com?

    YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

    ×

    Do you want to link to this External Site and leave Amgen.com?

    YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

    ×

     

    Access to Medicines Initiatives Outside the U.S.

    In light of the increasing global burden of cancer, cardiovascular disease, osteoporosis and other non-communicable diseases, Amgen's growing portfolio of biologic and biosimilar medicines holds the potential to make a significant difference for patients worldwide who are facing serious illnesses. "Reaching patients around the world who can benefit from our therapies and enabling patient access to our products are integral components of Amgen's ambition and long-term strategy," said Joshua Ofman, senior vice president of Global Health Policy.

    Amgen's Access to Medicines (ATM) approach is based on a recognition that patients living in low- and middle-income countries face multiple barriers to accessing biologic medicines. Those barriers include healthcare infrastructure and supply chain challenges to safely handle and administer biologics, as well as affordability in countries that lack adequate reimbursement and insurance systems.

    Together with partners and stakeholders, we are working to overcome such access challenges and barriers through a multi-faceted Access to Medicines approach tailored to the unique aspects of biologic medicines. Our approach is comprised of four core pillars. Click on a pillar below to learn more:

    Access to Medicines Structure and Management

    Amgen's ATM approach is a component of Amgen's holistic Sustainability Framework, which is governed by a cross-functional CEO-staff-level steering committee. In addition, a cross-functional collaboration has been established across Amgen teams that—as part of their respective business objectives—contribute to implementation of our ATM approach. This collaboration includes Global Value, Access and Policy, the Amgen Foundation, Corporate Affairs, Regulatory and International Policy, Advocacy, a Value Based Partnership team, our Biosimilars Division, Clinical Development, and our regional and local affiliate offices, which partner with local stakeholders to implement programs.

    国产对白在线正在播放